bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
- None.
- None.
Insights
The grant of a patent in India for bioAffinity Technologies' porphyrin compounds represents a strategic expansion of the company's intellectual property portfolio. This move could potentially open up a significant market for targeted cancer treatments in India, which is rapidly growing and has a high burden of cancer. The protection of their technology in a major market like India is likely to provide a competitive edge and can be seen as a positive signal to investors regarding the company's growth strategy.
From a market perspective, the patent grant can lead to partnerships or licensing agreements in the Indian market, enhancing revenue streams and diversifying the company's global footprint. It's also indicative of bioAffinity's commitment to international expansion, which can be a key driver for long-term growth and stability in share value.
The therapeutic approach of using chemotherapeutic agents conjugated to porphyrins for targeted cancer treatment can be a game-changer in oncology. Porphyrins have the ability to localize in cancer cells and by conjugating these with chemotherapy drugs, the treatment can directly target and kill cancer cells while potentially reducing the impact on healthy cells.
This could lead to treatments with fewer side effects and improved efficacy, which is a significant advancement over traditional chemotherapy. The patent grant is not only a validation of bioAffinity Technologies' innovative approach but also paves the way for further clinical development and trials, which are crucial for bringing new cancer therapies to market.
The grant of this patent in India could positively impact bioAffinity Technologies' financial outlook. Intellectual property rights are a key asset for biotech companies and strong patent protection can increase the company's valuation due to the potential for market exclusivity and reduced risk of competition. This can attract investment and partnership opportunities.
However, investors should consider the timeline and costs associated with bringing new treatments to market, including clinical trials, regulatory approvals and commercialization efforts. While the patent grant is a positive step, the actual financial impact will depend on successful product development and market adoption. The company's first product, CyPath® Lung, demonstrates their capability to reach the market, which may instill confidence in their pipeline's potential.
Indian Patent Office Grants Patent Related to Porphyrin Compounds for Targeted Cancer Treatment
The Indian patent, titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” is an important addition to bioAffinity Technologies’ patent portfolio, which includes 16 awarded
“India’s patent is an acknowledgement of the value of our ongoing research, development and commercialization of porphyrin-based diagnostics and targeted treatments for lung cancer and other diseases,” bioAffinity Technologies’ President and CEO Maria Zannes said. “We are committed to improving the outcome for cancer patients around the world, beginning with lung cancer, the deadliest cancer killer. Strong intellectual property protection for our innovative science benefits not only patients in need of treatment and their physicians, but also our research team and our shareholders as well.”
bioAffinity Technologies’ first product, CyPath® Lung, is a porphyrin-based diagnostic test for early-stage lung cancer. Physicians use CyPath® Lung for patients at high risk for developing lung cancer, often after recommended screening reveals indeterminate pulmonary lung nodules that may or may not be malignant. CyPath® Lung is a noninvasive test that uses advanced flow cytometry and artificial intelligence to differentiate patients with cancer from those who do not have the disease.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding improving the outcome for cancer patients around the world beginning with lung cancer and strong intellectual property protection benefitting patients, their physicians, the Company’s research team and the Company’s shareholders. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to develop and commercialize porphyrin-based diagnostics and targeted treatments for lung cancer and other diseases and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123142887/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies
FAQ
What is the ticker symbol for bioAffinity Technologies, Inc.?
What is the name of bioAffinity Technologies, Inc.'s first product?
What is the patent title for the Indian patent granted to bioAffinity Technologies, Inc.?
How many U.S. and foreign patents does bioAffinity Technologies, Inc. currently have?
What type of test is CyPath® Lung?
